NCT00163059已完成2 期
A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- MADRS
研究概览
简要总结
To determine if the NMDA antagonist, CP-101,606, is effective for depression
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary DSM-IV diagnosis of MDD
排除标准
- •Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
结局指标
主要结局
MADRS
次要结局
- HAM-D
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSDPTSDNCT05181995Aptinyx121
已完成
不适用
Evaluation of Dermasectan® versus SoC to compare efficacy and safety in treating atopic eczema (dermatitis) in adultsSkin and Connective Tissue DiseasesAtopic dermatitisISRCTN66879853ovintethical Pharma (Switzerland)42
进行中（未招募）
3 期
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsMyopiaNCT06209320Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.777
已完成
2 期
Study to evaluate the safety and efficacy of CCX168 in subjects with renal vasculitis on background cyclophosphamide treatmentRenal VasculitisCirculatory SystemRenal vasculitisISRCTN53663626ChemoCentryx, Inc. (USA)60
已完成
2 期
A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment of neurocognitive problems in tuberous sclerosisTuberous sclerosisNervous System DiseasesISRCTN09739757Cardiff University (UK)38